Key result
ACSS2 upregulation drives MASLD to MASH progression by activating AIF1 to induce chronic liver inflammation.
Why the study?
Inflammation drives progression from MASLD to MASH, but the molecular mechanisms initiating and sustaining liver inflammation remain poorly defined.
Answers are grounded in this paper and cite their sources.
ACSS2 may promote MASLD inflammation; hypothesis-generating and requires validation before any clinical consideration.
Inflammation is a pivotal driver of the progression from metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis (MASH), an aggressive form associated with substantial liver-related mortality. However, the molecular mechanisms underlying the initiation and persistence of liver inflammation remain poorly defined. Here, we demonstrated a previously unrecognized role for hepatic acetyl-CoA synthetase short-chain family member 2 (ACSS2) in MASH, showing that ACSS2 upregulation in patients exacerbates MASH progression by functioning as an epigenetic regulator, independent of its canonical lipogenic role. Mechanistically, ACSS2, in complex with lysine acetyltransferase 5 (KAT5), upregulates allograft inflammatory factor-1 (AIF1) transcription via histone crotonylation, thereby inducing liver inflammation and subsequently resulting in the aberrant accumulation of senescent hepatocytes, which further enhances proinflammatory cytokine production. This ultimately initiates a vicious cycle of chronic inflammation, which directly promotes the progression from simple steatosis to MASH. Thus, our work reveals a mechanistically defined and pivotal role for ACSS2 in promoting the MASLD-to-MASH transition, highlighting its potential as a compelling therapeutic target. Acetyl-CoA synthetase 2 (ACSS2) is known to regulate lipid metabolism. Here the authors identified ACSS2 drives MASH through nuclear translocation and complexes wiht KAT5 to crotonylate histones and activate AIF1.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2026) studied Metabolic dysfunction-associated steatotic liver disease (MASLD) to MASH transition. ACSS2 upregulation was evaluated on Liver inflammation and MASLD-to-MASH progression. ACSS2 upregulation drives the progression from MASLD to MASH by complexing with KAT5 to crotonylate histones and activate AIF1 transcription, inducing chronic liver inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: